ALL Hub

The ALL Hub was pleased to speak with Ibrahim Aldoss, City of Hope, Duarte, US. We asked, What are the recommendations for addressing challenges in implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)? In this interview, Aldoss discusses the challenges associated with implementing asparaginase-based regimens in AYA patients with ALL and shares recommendations to overcome them, which were recently established and published by a US consensus panel. This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The ALL Hub spoke with Luke Maese, University of Utah Huntsman Cancer Institute and Primary Children’s Hospital, Salt Lake City, US. We asked, What are the main barriers associated with implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with ALL. In this interview, Maese discussed the main challenges faced when treating AYA patients with ALL and the difficulties associated with facilitating the implementation of asparaginase-based regimens to treat this patient population. This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The ALL Hub was pleased to speak with Wendy Stock, the University of Chicago, US. We asked, What is the rationale for the use of pediatric-inspired asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)? In this interview, Stock reviews the clinical evidence and key considerations supporting this treatment approach in the AYA patient population. This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

During the ALL Hub Steering Committee meeting in November 2025, key opinion leaders met to discuss strategies to prevent relapse post hematopoietic stem cell transplantation (HSCT) / cellular therapy in B-cell acute lymphoblastic leukemia (B-ALL). The meeting opened with a presentation by Ibrahim Aldoss and featured a discussion including Charles Mullighan, José María Ribera, Sabina Chiaretti, Andre Baruchel, Wendy Stock, Daniel DeAngelo, and Anita Rijneveld. During his presentation, Aldoss highlighted that despite advances in multi-agent chemotherapy and novel immunotherapies allowing an increased number of patients to undergo allogeneic (allo) HSCT – a potentially curative approach in B-ALL – post-transplant relapse, as well as relapse following CAR T-cell therapy, remains a major cause of treatment failure. He discussed several studies exploring relapse-preventive measures post transplantation, including established strategies such as tyrosine kinase (TKI) maintenance in patients with Philadelphia-chromosome positive (Ph+) ALL, and newer strategies, such as the use of blinatumomab, inotuzumab ozogamicin, or prophylactic donor-derived CAR T-cell therapy, which have shown promising initial activity in patients with B-ALL. He also outlined the major considerations that influence the decision to initiate maintenance therapy after allo-HSCT or salvage therapy post-CAR T-cell therapy. This educational resource is independently supported by Pfizer. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion.

The ALL Hub was pleased to speak with Carmelo Rizzari, University of Milano-Bicocca, Monza, IT. We asked, How can therapeutic drug monitoring and premedication be applied in clinical practice to optimize pegaspargase treatment in patients with acute lymphoblastic leukemia (ALL)? This educational resource is independently supported by Servier. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The ALL Hub was pleased to speak with Luke Maese, University of Utah Huntsman Cancer Institute and Primary Children's Hospital, Salt Lake City, US. We asked, What are the key clinical considerations for asparaginase-based regimens in pediatric vs adolescent/young adult (AYA) patients with acute lymphoblastic leukemia (ALL)? This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

During the ALL Hub steering committee meeting, Mark Litzow chaired a discussion on consolidation therapy in newly diagnosed adult patients with Philadelphia chromosome-negative B-cell ALL.

During the ALL Hub Steering Committee meeting, Wendy Stock chaired a discussion on optimizing treatment for adults with relapsed/refractory Philadelphia chromosome-negative B-cell ALL.

During the ALL Hub Steering Committee meeting, André Baruchel chaired a discussion on “What are the key considerations when preparing patients with ALL for CAR T-cell therapy ?”, featuring Andrea Biondi, Anita Rijneveld, and José María Ribera. The discussion topics included: Key considerations when selecting patients: stable disease, degree of antigen expression, burden of bone marrow disease, and number of circulating tumor blasts Bridging therapy and lymphodepletion considerations The impact of prior exposure to blinatumomab and inotuzumab on CAR T-cell outcomes Indications for the use of tisagenlecleucel in pediatric ALL  Indications for the use of brexucabtagene autoleucel in adult ALL